Worth reading
36Immaterial
Scored from 5 of 6 sectionsDirection
Deterioration
Direction inferred from the company’s description.Scale
-154
¥ million (year-on-year change in net income)Wording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Financial results presentationFiscal year ending March 20263 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥0 million
Operating profit¥-1,295 million
Ordinary income¥-1,293 million
Net income¥-1,304 million
Selling, general and administrative expenses¥1,295 million
Full-year earnings forecast
Fiscal year ending March 2027
Net Sales
¥0 million
Operating profit
¥-1,965 million
Ordinary income
¥-1,947 million
Net income
¥-1,949 million
Research and development costs
¥1,680 million
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Increase in Selling, General and Administrative Expenses¥133 million
- Increase in R&D expenses¥114 million
New initiatives
- BP2202 clinical trials in the United States are scheduled to begin during fiscal 2026
- Creation of BP2203 and BP2204 based on the BP2202 platform
- Completion of the Phase I clinical trial for BP2301 and a subsequent-phase clinical trial by a development partner
- Exploration of out-licensing opportunities for BP1212 and BP1223
Number of employees
Number of Employees23 people
Record dateEnd of March 2026
| Item | Details |
|---|---|
| Document type | Financial results presentation |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Net Sales | ¥0 million |
| Operating profit | ¥-1,295 million |
| Ordinary income | ¥-1,293 million |
| Net income | ¥-1,304 million |
| Selling, general and administrative expenses | ¥1,295 million |
| Full-year earnings forecast | Subject Fiscal year ending March 2027 / Net Sales ¥0 million / Operating profit ¥-1,965 million / Ordinary income ¥-1,947 million / Net income ¥-1,949 million / Research and development costs ¥1,680 million |
| Breakdown of Factors Affecting the Change | Factors Increase in Selling, General and Administrative Expenses / Amount ¥133 million, Factors Increase in R&D expenses / Amount ¥114 million |
| Number of employees | Number of Employees 23 people / Record date End of March 2026 |
| New initiatives | BP2202 clinical trials in the United States are scheduled to begin during fiscal 2026, Creation of BP2203 and BP2204 based on the BP2202 platform, Completion of the Phase I clinical trial for BP2301 and a subsequent-phase clinical trial by a development partner, Exploration of out-licensing opportunities for BP1212 and BP1223 |
Items this document does not state (20)
Gross Profit MarginOperating profit marginResults for the three months of the current quarterProgress against full-year forecastSelf-assessment against the planSegment resultsKey KPIsUnit price and quantity metricsNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Selling, general and administrative expenses increased by ¥133 million and research and development expenses by ¥114 million, due to increased research and development funding for preparations for clinical trials of BP2202. Research and development expenses for the fiscal year ending March 2027 include ¥333 million recognized as a prepaid expense in the previous fiscal year and transferred to expenses in the current fiscal year, which does not involve a cash outflow.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.